ESH ALL 2021 | Importance of MRD monitoring in ALL
Selina Luger
• 14 May 2021
Selina Luger, MD, University of Pennsylvania, Philadelphia, PA, talks about the importance of minimal residual disease (MRD) in the management of patients with acute lymphoblastic leukemia (ALL). Prof. Luger compares how flow cytometry and PCR are used to measure MRD and how MRD status can be used to optimise the treatment plan for patients with ALL, especially those with Philadelphia chromosome-positive (Ph+) ALL. This interview took place during the 2021 European School of Hematology (ESH) 2nd Translational Research Conference on Acute Lymphoblastic Leukemia.
